Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Rochester, New York 14620


This study will evaluate the effect of oral eleclazine (GS-6615) on QTc interval, safety, and tolerability in adults with long QT2 syndrome.


Inclusion Criteria: - Individuals with an established diagnosis of LQT2 (by genotype testing) - Mean (of triplicate) QTc interval ≥ 480 msec for at least four out of seven time points, determined by standard 12-lead ECG, at screening Exclusion Criteria: - Known mutations associated with LQT1 or LQT3 - Known or suspected history of seizures or epilepsy - History of heart failure defined as New York Heart Association (NYHA) Class IV and/or known left ventricular ejection fraction (EF) ≤ 45% - Body mass index (BMI) ≥ 36 kg/m^2 at screening - Severe renal impairment at screening (defined as an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m^2, using the 4 Variable Modification of Diet in Renal Disease (MDRD) equation), as determined by the study center - Abnormal liver function tests at screening, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x upper limit of normal (ULN), or total bilirubin > 1.5 x ULN - An aborted cardiac arrest (ACA), implantable cardioverter-defibrillator (ICD) implantation, syncopal episode, or appropriate ICD therapy within 3 months prior to screening - Any other condition or circumstance that in the opinion of the investigator would preclude compliance with the study protocol



Primary Contact:

Study Director
Jennifer Hellawell, MD, FACC
Gilead Sciences

Backup Contact:


Location Contact:

Rochester, New York 14620
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.